Brief: Rigel Doses First Patient In Phase 1B Study Of R289 For The Treatment Of Lower-Risk Myelodysplastic Syndromes
15/12/2022 14:44
Dec 15 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL DOSES FIRST PATIENT IN PHASE 1B STUDY OF R289 FOR
THE
TREATMENT OF LOWER-RISK MYELODYSPLASTIC SYNDROMES
Source text for Eikon: ID:nPn3jKWfra
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)